21st.BIO
Carry the process from bench to partner tank
- Precision Fermentation
- Søborg (Copenhagen), Denmark
- February 2026
A4BEE prepared this analysis from publicly available sources. It reflects our own reading of 21st.BIO's published strategy and is not endorsed by, or produced in cooperation with, 21st.BIO. Company website
Strategic priorities
21st.BIO is a Danish precision-fermentation company founded in 2020, built to move novel proteins across the gap between a working strain in the lab and economically viable production at industrial scale. It licenses optimised strains and fermentation processes to partners who manufacture at kiloton volumes, so its revenue follows what those partners produce rather than the discovery itself. The company is backed by Novo Holdings, the investment arm of the Novo Nordisk Foundation, with roughly $153 million raised between 2020 and 2025.
The business runs on two sites that hold two different kinds of data. R&D and high-throughput strain engineering sit in Davis, California, near the UC Davis agricultural-technology cluster; pilot manufacturing and downstream process development sit in Søborg, Denmark, where a 3,000-litre pilot plant was unveiled in May 2024. Strain and genomic data is generated on one side of that pair and bioreactor process data on the other, which puts a premium on relating a fermentation outcome back to the strain that produced it.
The production strains are filamentous fungi, principally Aspergillus oryzae, chosen for high titre but sensitive to shear, oxygen transfer and heat as volumes rise. 21st.BIO holds Self-Affirmed GRAS status in the US for animal-free whey protein and is preparing for FDA notifications while EU rules diverge. Across all three fronts — the licensee hand-off, the two-site data pair, and the regulatory record — the same underlying capability recurs: process and strain data that can be read, matched and carried forward outside the equipment that produced it.
-
01
Industrial scale-up
Moving from laboratory-scale strain development to pilot and industrial fermentation through the 3,000-litre Søborg plant, positioned as a launchpad for precision-fermentation processes that partners can then run at 100,000-litre-plus volumes.
-
02
Lab automation and R&D data
Investing in automated systems — including a 2024 stake in the lab-imaging company Reshape Biotech — to lift the throughput of strain analysis and phenotypic screening and to build a data foundation across the Davis and Søborg sites.
-
03
Licensing and technology transfer
A licensing model that hands optimised fermentation processes to contract manufacturers worldwide. Because revenue is royalty-based, the speed and reliability of each transfer to a partner site directly shapes commercial outcomes.
-
04
Regulatory standing and strain safety
A mycotoxin-free Aspergillus oryzae lineage, Self-Affirmed GRAS status in the US, and active engagement with EU frameworks for strain-level safety — presented by the company as a gold standard for safe novel-protein production.
Challenges we see
- Operations Manufacturing
Handing a process to a contract manufacturer
Moving an optimised fermentation process from 21st.BIO to a contract manufacturer is the company's core commercial activity, and the licensing model is royalty-based. Industry practice for these hand-offs still leans on manual documentation and non-standardised data formats between partners, and unstructured transfers are a recognised cause of budget overruns and multi-month delays in the sector.
Because revenue follows the licensee's production rather than the transfer itself, the time taken to bring a partner site to a reproducible run sits directly on the revenue timeline.
- Operations Manufacturing
Holding filamentous fungi within range during scale-up
21st.BIO's production strains are filamentous fungi, principally Aspergillus oryzae, selected for high titre. The company's CSO describes them as high-performance but sensitive: shear stress, oxygen transfer and heat accumulation all have to be held within a narrow band as volumes rise from bench to the 3,000-litre pilot plant and beyond.
Parameters that stay in range by themselves at pilot scale need active management at production scale, which moves the emphasis from post-run analysis to signals read during the run.
- Data Integration
Joining strain data in California to fermentation data in Denmark
R&D and strain engineering run in Davis, California; pilot manufacturing and downstream process development run in Søborg, Denmark. Genomic and metabolic data is generated at one site and bioreactor sensor data at the other, across a nine-hour time difference, with the two estates described as organisationally and technically separate.
Relating a fermentation outcome back to the strain and conditions that produced it is currently a manual assembly step, so the link between a run in Søborg and a strain from Davis is rebuilt each time it is needed rather than being available as data.
- Digital Operations
Raising throughput in strain screening
The R&D workflow generates each data point in strain analysis and phenotypic monitoring with substantial hands-on work. The company's 2024 investment in the automated-imaging firm Reshape Biotech signals a move to take manual effort out of that loop.
Screening capacity sets how many strain variants can be evaluated, and therefore how much of the design space is explored before a candidate is chosen for scale-up.
- Compliance Regulatory
Keeping strain and batch records audit-ready
Holding Self-Affirmed GRAS status in the US and preparing for FDA notifications calls for an unbroken, auditable record of strain development and batch consistency, while EU regulatory divergence adds a second documentation track for market access.
The record has to be assembled continuously as strains develop and batches run, so that a notification draws on evidence already in place rather than one reconstructed at notification time.
Opportunities, by urgency and business impact
Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.
-
Standardising the technology-transfer package to partner sites
Transfer of a fermentation process to a contract manufacturer currently rests on manual documentation and process descriptions that each receiving site adapts by hand. Because royalties follow the licensee's production, the interval between hand-off and a reproducible run sits on the revenue timeline.
A parameterised digital transfer package — process description, equipment specifications, critical quality attributes and version-controlled parameters in one structured, access-controlled form — gives every receiving site the same reference to match against, so the work at each site is verification rather than reconstruction.
- 21st.BIO, Get Started & Scale brochure, September 2024
- The company's CEO, on production cost and scale-up economics
-
Reading fermentation signals while the pilot batch runs
Filamentous fungi are sensitive to shear, oxygen transfer and heat as scale rises, and today a deviation in the 3,000-litre pilot plant is largely read from the record after the run rather than during it.
Instrumenting the pilot bioreactors and streaming their data into a monitored model — with the normal operating envelope built from prior runs — lets drift be flagged against the batch that is still in the tank, so operators see a signal in minutes instead of a finding in a later report.
- The company's CSO, on strain sensitivity during scale-up
- 21st.BIO Søborg 3,000-litre pilot plant, unveiled May 2024
-
Putting Davis strain data and Søborg process data into one model
Strain, genomic and metabolic data from Davis and bioreactor sensor data from Søborg sit in separate systems, so comparing a fermentation result against the strain that produced it is a manual data pull across two sites and a time-zone gap.
An agreed model for strain, run, vessel, parameter and result lets both sites load against one structure, so a run in Denmark can be queried against a strain from California directly instead of being reconciled by hand for each question.
- 21st.BIO dual-site model, Davis R&D and Søborg pilot manufacturing
- DTU sector report, Automating life science R&D and manufacturing, 2021
-
Raising the throughput of strain screening
Each data point in phenotypic screening takes significant hands-on work, which sets how many strain variants can be evaluated before a candidate is selected.
Connecting automated imaging such as Reshape Biotech into a shared R&D data layer captures phenotypic results without manual transcription and lets screening run at higher throughput, so more of the design space is covered per campaign.
- 21st.BIO investment in Reshape Biotech, April 2024
-
Assembling the strain and batch record as it is created
GRAS maintenance, FDA notification preparation and EU submissions each draw on a continuous, auditable record of strain development and batch consistency; where that record is compiled for review, assembling it is a separate task from the work it documents.
Capturing strain-development and batch data with its own audit trail as it is generated means the evidence chain for a notification is already in place and readable end to end, rather than reconstructed against a deadline.
- 21st.BIO Self-Affirmed GRAS status for animal-free whey protein
- 21st.BIO gold-standard precision-fermentation safety statement
What we'd propose
- Digital CDMO
A standard digital technology-transfer package for partner sites
A structured, version-controlled transfer package that carries a fermentation process to a contract manufacturer as data: process description, equipment specifications, critical quality attributes and recorded process conditions in one access-controlled form, so every receiving site matches against the same reference.
-
Parameterised transfer templates
Define process descriptions, equipment specifications and critical quality attributes as a parameterised template, so each transfer produces a package in the same shape instead of a bespoke document set the receiving site has to re-interpret.
-
Version control and access control
Hold process parameters and protocol documents under version control with role-based access, so a receiving site always works from the current recipe and 21st.BIO keeps a record of what was shared, with whom, and when.
-
Auditable hand-off workflow
Track each transfer step with an immutable log, so the reference every partner site is matched against — and the conditions it was matched under — is recorded rather than remembered.
- Each receiving site verifies against a common reference instead of adapting a bespoke document set.
- The interval between hand-off and a reproducible run — the part of the revenue timeline 21st.BIO can influence — shortens.
- What was transferred, to whom and under which parameters is recorded rather than reconstructed later.
-
- Digital CDMO
Real-time monitoring for the pilot fermentation plant
Instrument the 3,000-litre pilot bioreactors, bring their process data into one time-series model, and run deviation detection against the batch currently in the tank, so a signal about a sensitive fungal run arrives while the batch is still live.
-
Bioreactor data acquisition
Connect the pilot bioreactor sensors and controllers through OPC UA (Open Platform Communications Unified Architecture) so process values leave the equipment in a documented, vendor-neutral form rather than staying inside a closed control system.
-
Deviation detection against a live batch
Build the normal operating envelope for each critical parameter from prior runs, then flag drift in shear, oxygen transfer or temperature against the current batch, so a signal reaches operators in minutes rather than in a post-run report.
-
Non-invasive vision monitoring
Add external camera-based monitoring for foam and other visual indicators that in-tank probes do not capture, giving operators an early read on conditions before they threaten a batch of high-value strain.
- Deviations surface against the batch that is running, not the one already lost.
- One set of pilot-plant process data serves operations, process development and R&D instead of three separate extracts.
- The conditions behind a good or bad run are recorded as data, ready to compare against the next campaign.
-
- Enterprise AI
One data model for Davis strain data and Søborg process data
An ontology-based data platform that defines the entities both sites share — strain, run, vessel, parameter, result — once, then loads Davis R&D data and Søborg pilot-plant data against that single model, so a fermentation outcome can be queried against the strain that produced it.
-
Shared strain-to-process ontology
Define strain, run, vessel, parameter and result as explicit entities with agreed relationships, so a query written once returns comparable answers across both sites instead of two local dialects of the same data.
-
Pipelines from lab and pilot systems
Build ingestion for genomic, metabolic and phenotypic data from Davis and for bioreactor process data from Søborg, with schema validation at the boundary so bad records fail loudly rather than propagate quietly.
-
Cross-site query and retrieval
Expose the model so a process scientist can relate a Søborg run to a Davis strain directly, without a manual data pull across the time-zone gap for each question.
- A fermentation result can be traced to its strain and conditions as a query, not a manual assembly.
- Integration is done once against a shared model instead of once per point-to-point link between the sites.
- New vessels, strains and future sites attach to the model rather than triggering another reconciliation.
-
- Digital Lab
Automated data capture for strain screening
Integrate automated imaging such as Reshape Biotech and the analytical instruments in Davis into a shared R&D data layer, so phenotypic results are captured as data at source and screening runs at higher throughput without adding manual transcription.
-
Imaging and instrument integration
Connect automated imaging and analytical instruments so results arrive with strain identity, method and timestamp attached, instead of being read off a screen and re-keyed into another system.
-
Shared R&D data layer
Bring genomic, metabolic and phenotypic results into one queryable store, so strain candidates can be compared across experiments rather than within single runs.
-
Screening workflow orchestration
Schedule, track and capture results for high-throughput screening campaigns with full traceability, so throughput rises without loss of provenance.
- Phenotypic results are captured as data rather than transcribed, so screening scales without proportional manual effort.
- More strain variants can be evaluated per campaign, widening the design space explored before selection.
- Every screening result carries its strain, method and timestamp, ready to feed the shared model.
-
- Agents
AI agents for strain and batch documentation
Narrow, reviewable agents that take the repetitive part of the regulatory record: drafting strain-development and batch summaries from source data, checking a document against its template before review, and finding every record a strain or specification change affects. A named person approves every output.
-
Drafting from source records
Generate the first draft of a strain-development or batch document directly from the underlying system data, so the author edits and judges rather than assembles from scratch.
-
Template and completeness checking
Check a submitted document against its template and the relevant regulatory checklist, returning missing or inconsistent sections before it enters the human review queue.
-
Change-impact search across records
When a strain lineage, method or specification changes, retrieve every controlled record that references it so the scope of an update — for a GRAS maintenance file or an FDA notification — is known at the start.
- Documents reach review complete, so the record for a notification is kept current rather than assembled against a deadline.
- The scope of a strain or specification change is established by search rather than by recollection.
- Every output traces back to the source records it came from and is signed off by a named reviewer.
-
Where QB Systems fits
Alongside our services we build QB Systems, hardware and software for bioprocess control. QB Systems is a product brand of A4BEE Sp. z o.o.
- 21st.BIO's R&D in Davis runs bioprocess and strain-development work at the bench and screening scale that QB Modules and QB Control are built for — the point where a control and sensor layer captures process data before a candidate is taken to pilot.
- Filamentous-fungi development involves fermentation, sampling and downstream filtration on vessels that, at development scale, are the retrofit target QB addresses without replacing the equipment.
- The 3,000-litre Søborg pilot plant and any partner production tanks run well above the QB range; QB applies to 21st.BIO's own development and screening vessels, not to pilot or licensee production, and production-scale QB is on the roadmap rather than available today.
- Because every partner transfer is matched against 21st.BIO's own recorded development conditions, capturing reproducible recipes and process data at development scale — where QB sits — strengthens the reference each receiving site is matched to.
-
QB Control
Software-defined bioprocess control — the hardware setup is described in software, so one platform runs different vessels and processes.
-
QB Modules
Modular hardware: edge controller, peristaltic pumps, multisensor, pressure sensor, multiscale and light — combined per process.
- Applications
- Bioreactors
Software-defined control for a bioreactor — a new QB vessel, an upgrade to one you have, or a retrofit of the existing PLC.
- Automated sampling
Automated sampling from 4–18 sources, aseptic-capable and up to 72 hours unattended. Works with any vendor's bioreactor.
- Filtration (TFF)
Benchtop tangential flow filtration for concentration, diafiltration and buffer exchange.
- Deployment
- Retrofit
Existing equipment keeps running; QB takes over the PLC, or reads from it without touching control.
- Scale
- Benchtop (1–8 L)
Glass vessels with the complete hardware and software stack. This is the core range for development work.
Digital maturity: today and target
Scored out of 100 across six dimensions. The target is what 21st.BIO's own published ambition implies — not a perfect score.
- Cross-site data model 25 → 80
- Strain and process data are generated on two sites with a nine-hour gap and described as organisationally and technically separate, so relating a Søborg run to a Davis strain is a manual pull rather than a query. The shared-model work is ahead of the company rather than behind it.
- Lab automation 35 → 85
- The 2024 Reshape Biotech investment signals intent to automate imaging and screening, but each phenotypic data point still takes substantial hands-on work today.
- Pilot process monitoring 30 → 82
- The 3,000-litre pilot plant is a current-generation biological facility, but with deviations largely read after the run there is room to move toward signals read during it for sensitive fungal strains.
- Technology-transfer readiness 30 → 85
- Transfer to contract manufacturers rests on manual documentation and per-site adaptation; because the model is royalty-based, a structured, version-controlled package favours a faster, more repeatable hand-off.
- Regulatory record automation 30 → 82
- GRAS maintenance and FDA notification preparation, alongside EU divergence, favour a strain and batch record generated with its own audit trail over one compiled for each review.
- IP and protocol control 30 → 80
- The mycotoxin-free strain lineage and its protocols are the company's core asset; version-controlled, access-controlled protocol sharing during licensing protects that asset through each transfer.
Check this yourself
Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.
-
Self-assessment
Electronic Batch Record (eBR) Readiness
Check how far your batch records are from paperless, and what the next step is.
-
Self-assessment
Data & AI Maturity
See how ready your data actually is for the AI work you're planning.
-
Market comparison
European CDMOs Compared
The 2026 landscape: who does what, at what scale.
-
Market comparison
Pharma Data Platform Use Cases — Ranked
Use cases ranked by how hard they are against what they're worth.
Think we've read this right?
Talk to usRelated reading
-
Still biotech or already techbio?
The results of a Tech Imperatives for biotech 2022 report indicate changes in biotech production and management.
-
Vision systems and foam detection
Machine vision systems enhance industrial safety and quality by detecting defects and foam in real time for efficient, automated processes.
-
Digital Twin Maturity Model – self-assessment tool
Initially, defining what a digital twin even is seemed simple - we have a real product and its virtual counterpart, and we combine the two.
-
Developing a data and technology-driven flexible lab operations model
Now, when it becomes clear to the biotech companies that only by sharing the data they can thrive, everyone is looking for a solution.
-
Why Lab Digitization Stalls: 426 Instruments Rated for Integration Effort
Connecting a lab instrument is rarely hard because of the instrument. We rated 426 instruments from 154 vendors to show how much work each one really takes.
This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with 21st.BIO, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].